Skip to main content

Table 2 Proportion of serotypablea lytA-positive samples (n = 607) by lytA cycle threshold value (Ct-value) among patients hospitalized with severe acute respiratory illness at Chris Hani-Baragwanath Academic Hospital, Soweto, South Africa, 2009–2012

From: Assessing the impact of pneumococcal conjugate vaccines on invasive pneumococcal disease using polymerase chain reaction-based surveillance: an experience from South Africa

lytA Ct-value

Serotypablea lytA-positive samples

n/N (%)

OR (95 % CI)

p

≤30

54/71 (76.1)

Reference

-

31

20/23 (86.9)

2.1 (0.6-7.9)

0.275

32

22/28 (78.6)

1.2 (0.4-3.3)

0.790

33

32/36 (88.9)

2.5 (0.8-8.1)

0.123

34

28/42 (66.7)

0.6 (0.3-1.5)

0.281

35

31/57 (54.4)

0.4 (0.2-0.8)

0.011

36

29/72 (40.3)

0.2 (0.1-0.4)

<0.001

37

28/93 (30.1)

0.1 (0.07-0.3)

<0.001

38

27/134 (20.1)

0.08 (0.04-0.15)

<0.001

39

8/51 (15.7)

0.06 (0.02-0.14)

<0.001

  1. Abbreviations: OR: odds ratio; CI: confidence interval
  2. aSerotypable samples were samples tested with the serotyping assay from which a serotype/serogroup included in the assay was detected